<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s0{background-color:#ffffff;text-align:left;color:#222222;font-family:'docs-Google Sans',Arial;font-size:11pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="71304636C0" style="width:534px;" class="column-headers-background">A</th><th id="71304636C1" style="width:534px;" class="column-headers-background">B</th><th id="71304636C2" style="width:100px;" class="column-headers-background">C</th></tr></thead><tbody><tr style="height: 20px"><th id="71304636R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Thalassaemia in Pregnancy</td><td class="s1" dir="ltr">Source</td><td class="s1" dir="ltr"> GTG 66</td></tr><tr style="height: 20px"><th id="71304636R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s1"></td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s1" dir="ltr">Summary:</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s1" dir="ltr">PRECONCEPTION CARE: <br>Counsel re pregnancy intentions at each visit w thalassaemia team, incl screening for end-organ damage and pre-pregnancy optimisation with guideline-directed management.<br>Advise contraception until planning pregnancy.<br>Aggressive preconception chelation to reduce iron burden and end-organ damage.<br>Multimodal optimisation:<br>Diabetes - under specialist, aim good control with fructosamine &lt; 300<br>Euthyroid<br>Cardiac - under specialist, ECG / echo / T2 MRI pre-pregnancy<br>Liver - pre-preg Ferriscan / screen for cirrhosis<br>Bone density - scan for osteoporosis and optimse vitamin D<br>Atypical antibodies - screen for traunfusion sensitisation<br>Discontinue teratogenic iron chelators 3 months pre-pregnancy<br>Partner screening +/- IVF / ICSI / PGD<br>Hep B / Hep C screening<br>Splenectomy - vaccinations and penicillin prophylaxis<br><br>Folic acid - high dose until 12 weeks<br>ANC - specialist MDT (mat med) incl cardiac and thyroid care<br>Serial scans incl 7-9 week confirmation of viability, growth from 24 weeks to delivery<br>Hb - aim &gt; 100 pre-transfusion, offer regular transfusions<br>VTE prophylaxis - LDA if either splenectomy or plt &gt;600, LMWH if both, consider LMWH for all admissions<br>Consider chelation if overloaded, haem to lead on this<br>Inform senior midwifery / obs / anaesthetic / haem staff on admission to delivery suite.<br>X-match if red cell antibodies present<br>If thalassameia major - IV desferrioxamine 2g over 24 hours during labour<br>Active 3rd to minimise blood loss<br>Postnatal - high risk VTE, encourage breastfeeding<br></td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s1" dir="ltr"></td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s1" dir="ltr"></td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s1" dir="ltr"></td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s1" dir="ltr"></td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s1" dir="ltr">PRECONCEPTION CARE: At each visit with the thalassaemia team, there should be a discussion and documentation of intentions regarding pregnancy. This should include screening for end-organ damage and optimisation of complications prior to embarking on any pregnancy. Each Specialist Haemoglobinopathy Centre should have a guideline for the management of pregnant women with thalassaemia. Women should be advised to use contraception despite the reduced fertility associated with thalassaemia. Aggressive chelation in the preconception stage can reduce and optimise body iron burden and reduce<br>end-organ damage. </td><td class="s1" dir="ltr">PRECONCEPTION CARE: <br>Counsel re pregnancy intentions at each visit w thalassaemia team, incl screening for end-organ damage and pre-pregnancy optimisation with guideline-directed management.<br>Advise contraception until planning pregnancy.<br>Aggressive preconception chelation to reduce iron burden and end-organ damage.</td><td class="s1">PRECONCEPTION CARE: <br>Counsel re pregnancy intentions at each visit w thalassaemia team, incl screening for end-organ damage and pre-pregnancy optimisation with guideline-directed management.<br>Advise contraception until planning pregnancy.<br>Aggressive preconception chelation to reduce iron burden and end-organ damage.<br></td></tr><tr style="height: 20px"><th id="71304636R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s1" dir="ltr">DIABETES: Diabetes is common in women with thalassaemia. Women with diabetes should be referred to a diabetologist. Good glycaemic control is essential prepregnancy. Women with established diabetes mellitus should ideally have serum fructosamine concentrations &lt; 300 nmol/l for at least 3 months prior to conception. This is equivalent to an HbA1c of 43 mmol/mol.</td><td></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s1" dir="ltr">THYROID: Thyroid function should be determined. The woman should be euthyroid prepregnancy</td><td class="s1" dir="ltr"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s1" dir="ltr">CARDIAC: All women should be assessed by a cardiologist with expertise in thalassaemia and/or iron overload prior to embarking on a pregnancy. An echocardiogram and an electrocardiogram (ECG) should be performed as well as T2* cardiac MRI.</td><td class="s1" dir="ltr"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s1" dir="ltr">LIVER: Women should be assessed for liver iron concentration using a FerriScan® or liver T2*. Ideally the liver iron should be &lt; 7 mg/g (dry weight) (dw). Liver and gall bladder (and spleen if present) ultrasound should be used to detect cholelithiasis and evidence of liver cirrhosis due to iron overload or transfusion-related viral hepatitis.</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s1" dir="ltr">BONE DENSITY: All women should be offered a bone density scan to document pre-existing osteoporosis. Serum vitamin D concentrations should be optimised with supplements if necessary</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s1" dir="ltr">RED CELL ANTIBODIES: ABO and full blood group genotype and antibody titres should be measured.</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s1" dir="ltr">IRON CHELATORS: Iron chelators should be reviewed and deferasirox and deferiprone ideally discontinued 3 months before conception.</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s1" dir="ltr">GENETIC SCREENING: If the partner is a carrier of a haemoglobinopathy that may adversely interact with the woman’s genotype then genetic counselling should be offered. In vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) with a pre-implantation genetic diagnosis (PGD) should be considered in the presence of haemoglobinopathies in both partners so that a homozygous or compound heterozygous pregnancy can be avoided. Egg and sperm donors considering IVF should be screened for haemoglobinopathies. In an affected mother, there is a risk of serious haemoglobinopathy if the father / donor has the following condition as a carrier or sufferer: Beta thalassaemia HbS HbE Delta beta thalassaemia Hb Lepore HbO Arab Hb Constant Spring. In an affected mother, there is a mild to moderate risk of disorder if the father / donor has the following condition as a carrier or sufferer: HbC or another variant not described above. </td><td class="s1" dir="ltr">Multimodal optimisation:<br>Diabetes - under specialist, aim good control with fructosamine &lt; 300<br>Euthyroid<br>Cardiac - under specialist, ECG / echo / T2 MRI pre-pregnancy<br>Liver - pre-preg Ferriscan / screen for cirrhosis<br>Bone density - scan for osteoporosis and optimse vitamin D<br>Atypical antibodies - screen for traunfusion sensitisation<br>Discontinue teratogenic iron chelators 3 months pre-pregnancy<br>Partner screening +/- IVF / ICSI / PGD<br>Hep B / Hep C screening<br>Splenectomy - vaccinations and penicillin prophylaxis<br></td><td class="s1">Multimodal optimisation:<br>Diabetes - under specialist, aim good control with fructosamine &lt; 300<br>Euthyroid<br>Cardiac - under specialist, ECG / echo / T2 MRI pre-pregnancy<br>Liver - pre-preg Ferriscan / screen for cirrhosis<br>Bone density - scan for osteoporosis and optimse vitamin D<br>Atypical antibodies - screen for traunfusion sensitisation<br>Discontinue teratogenic iron chelators 3 months pre-pregnancy<br>Partner screening +/- IVF / ICSI / PGD<br>Hep B / Hep C screening<br>Splenectomy - vaccinations and penicillin prophylaxis<br><br></td></tr><tr style="height: 20px"><th id="71304636R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s1" dir="ltr">IMMUNISATION and PROPHYLAXIS: Hepatitis B vaccination is recommended in HBsAg negative women who are transfused or may be transfused. Hepatitis C status should be determined. All women who have undergone a splenectomy should take penicillin prophylaxis or equivalent. All women who have undergone a splenectomy should be vaccinated for pneumococcus and Haemophilus influenzae type b if this has not been done before.</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s1" dir="ltr">FOLIC ACID: 5mg daily preconceptually and in 1st trimester is recommended.</td><td class="s1" dir="ltr">Folic acid - high dose until 12 weeks</td><td class="s1">Folic acid - high dose until 12 weeks<br></td></tr><tr style="height: 20px"><th id="71304636R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s1" dir="ltr">ANC: Women with thalassaemia should be reviewed monthly until 28 weeks of gestation and fortnightly thereafter. The multidisciplinary team should provide routine as well as specialist antenatal care. Women with both thalassaemia and diabetes should have monthly assessment of serum fructosamine concentrations and review in the specialist diabetic pregnancy clinic. All women with thalassaemia major should undergo specialist cardiac assessment at 28 weeks of gestation and thereafter as appropriate. Thyroid function should be monitored during pregnancy in hypothyroid patients</td><td class="s1" dir="ltr">ANC - specialist MDT (mat med) incl cardiac and thyroid care</td><td class="s1">ANC - specialist MDT (mat med) incl cardiac and thyroid care<br></td></tr><tr style="height: 20px"><th id="71304636R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s1" dir="ltr">SONOGRAPHY: Women should be offered an early scan at 7–9 weeks of gestation. In addition to the routine first trimester scan (11–14 weeks of gestation) and a detailed anomaly scan at 18–20+6 weeks of gestation, women should be offered serial fetal biometry scans every 4 weeks from 24 weeks of gestation.</td><td class="s1" dir="ltr">Serial scans incl 7-9 week confirmation of viability, growth from 24 weeks to delivery</td><td class="s1">Serial scans incl 7-9 week confirmation of viability, growth from 24 weeks to delivery<br></td></tr><tr style="height: 20px"><th id="71304636R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s1" dir="ltr">TRANSFUSION: All women with thalassaemia major should be receiving blood transfusions on a regular basis aiming for a pretransfusion haemoglobin of 100 g/l. In thalassaemia intermedia, if there is worsening maternal anaemia or evidence of FGR, regular transfusions should be considered. If a woman with thalassaemia intermedia starts transfusion, haemoglobin targets are managed as for thalassaemia major. Women with thalassaemia intermedia who are asymptomatic with normal fetal growth and low haemoglobin should have a formal plan outlined in the notes with regard to blood transfusion in late pregnancy</td><td class="s1" dir="ltr">Hb - aim &gt; 100 pre-transfusion, offer regular transfusions</td><td class="s1">Hb - aim &gt; 100 pre-transfusion, offer regular transfusions<br></td></tr><tr style="height: 20px"><th id="71304636R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s1" dir="ltr">THROMBOPROPHYLAXIS: Women with thalassaemia who have undergone splenectomy or have a platelet count greater than 600 x 109 /l should commence or continue taking low-dose aspirin (75 mg/day). Women with thalassaemia who have undergone splenectomy and have a platelet count above 600 x 109 /l should be offered low-molecular-weight heparin thromboprophylaxis as well as low-dose aspirin (75 mg/day). Women with thalassaemia who are not already using prophylactic low-molecular-weight heparin should be advised to use it during antenatal hospital admissions.</td><td class="s1" dir="ltr">VTE prophylaxis - LDA if either splenectomy or plt &gt;600, LMWH if both, consider LMWH for all admissions</td><td class="s1">VTE prophylaxis - LDA if either splenectomy or plt &gt;600, LMWH if both, consider LMWH for all admissions<br></td></tr><tr style="height: 20px"><th id="71304636R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s1" dir="ltr">ANTENATAL IRON CHELATION:Iron chelation therapy is complex and should be tailored to the needs of the individual woman</td><td class="s1" dir="ltr">Consider chelation if overloaded, haem to lead on this</td><td class="s1">Consider chelation if overloaded, haem to lead on this<br></td></tr><tr style="height: 20px"><th id="71304636R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s1" dir="ltr">MYOCARDIAL IRON: Women with myocardial iron loading should undergo regular cardiology review with careful monitoring of ejection fraction during the pregnancy as signs of cardiac decompensation are the primary indications for intervention with chelation therapy. Those women at highest risk of cardiac decompensation should commence low-dose subcutaneous desferrioxamine (20 mg/kg/day) on a minimum of 4–5 days a week under joint haematology and cardiology guidance from 20–24 weeks of gestation.</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s1" dir="ltr">LIVER IRON: Women with severe hepatic iron loading should be carefully reviewed and consideration given to lowdose desferrioxamine iron chelation from 20 weeks.</td><td class="s1"></td><td class="s1"></td></tr><tr style="height: 20px"><th id="71304636R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s1" dir="ltr">INTRAPARTUM CARE: Timing of delivery should be in line with national guidance. Senior midwifery, obstetric, anaesthetic and haematology staff should be informed as soon as the woman is admitted to the delivery suite. In the presence of red cell antibodies, blood should be cross-matched for delivery since this may delay the availability of blood. Otherwise a group and save will suffice. In women with thalassaemia major intravenous desferrioxamine 2 g over 24 hours should be administered for the duration of labour. Continuous intrapartum electronic fetal monitoring should be instituted. Thalassaemia in itself is not an indication for caesarean section. Active management of the third stage of labour is recommended to minimise blood loss.</td><td class="s1" dir="ltr">Inform senior midwifery / obs / anaesthetic / haem staff on admission to delivery suite.<br>X-match if red cell antibodies present<br>If thalassameia major - IV desferrioxamine 2g over 24 hours during labour<br>Active 3rd to minimise blood loss</td><td class="s1">Inform senior midwifery / obs / anaesthetic / haem staff on admission to delivery suite.<br>X-match if red cell antibodies present<br>If thalassameia major - IV desferrioxamine 2g over 24 hours during labour<br>Active 3rd to minimise blood loss<br></td></tr><tr style="height: 20px"><th id="71304636R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s1" dir="ltr">POSTPARTUM CARE: Women with thalassaemia should be considered at high risk for venous thromboembolism. Breastfeeding is safe and should be encouraged.</td><td class="s1" dir="ltr">Postnatal - high risk VTE, encourage breastfeeding</td><td class="s1">Postnatal - high risk VTE, encourage breastfeeding<br></td></tr></tbody></table></div>